shutterstock_460985854_rawf8
rawf8 / Shutterstock.com
14 December 2020Big PharmaMicheline Gravelle and Iris Cheung

Pricing, patents and the PMPRB in Canada

The price of patented medicines in Canada is regulated by the Patented Medicine Prices Review Board (PMPRB), an independent, quasi-judicial body established under the Patent Act to ensure the prices of patented medicines are not excessive.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
26 October 2020   The final version of guidelines issued by Canada’s federal drug price regulator last week has caused uproar among the pharma industry.
Americas
3 March 2015   Section 8 of Canada’s Patented Medicines (Notice of Compliance) Regulations is a unique provision under which an innovator can be liable for a generic’s losses that result from a delay in coming to market, as Gunars Gaikis explains

More on this story

Americas
26 October 2020   The final version of guidelines issued by Canada’s federal drug price regulator last week has caused uproar among the pharma industry.
Americas
3 March 2015   Section 8 of Canada’s Patented Medicines (Notice of Compliance) Regulations is a unique provision under which an innovator can be liable for a generic’s losses that result from a delay in coming to market, as Gunars Gaikis explains

More on this story

Americas
26 October 2020   The final version of guidelines issued by Canada’s federal drug price regulator last week has caused uproar among the pharma industry.
Americas
3 March 2015   Section 8 of Canada’s Patented Medicines (Notice of Compliance) Regulations is a unique provision under which an innovator can be liable for a generic’s losses that result from a delay in coming to market, as Gunars Gaikis explains